September 7, 2021
Revolution Medicines to Present at H.C. Wainwright 23rd Annual Global Investment Conference
August 11, 2021
Revolution Medicines Reports Second Quarter Financial Results and Update on Corporate Progress
August 4, 2021
Revolution Medicines to Report Financial Results for Second Quarter 2021 After Market Close on August 11, 2021
June 24, 2021
Revolution Medicines Announces Publication of Scientific Paper Describing Novel Class of Anti-Tumor Compounds Targeting mTORC1
June 10, 2021
Revolution Medicines to Host Science Talk Webcast Highlighting Learnings from Recent Preclinical and Clinical Studies of RAS Inhibitors
June 2, 2021
Revolution Medicines to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference
May 18, 2021
Revolution Medicines to Participate in Cowen 2nd Annual Virtual Oncology Innovation Summit
May 10, 2021
Revolution Medicines Reports First Quarter Financial Results and Update on Corporate Progress
May 3, 2021
Revolution Medicines Highlights Slate of Diverse Board of Directors Nominees for Upcoming 2021 Annual Shareholder Meeting
April 21, 2021
Revolution Medicines Announces Dosing of First Patient in Phase 1/1b Clinical Study of RMC-5552 in Patients with Advanced Solid Tumors